Stelis Biopharma Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Stelis Biopharma's estimated annual revenue is currently $42.4M per year.(i)
  • Stelis Biopharma's estimated revenue per employee is $77,500

Employee Data

  • Stelis Biopharma has 547 Employees.(i)
  • Stelis Biopharma grew their employee count by 15% last year.

Stelis Biopharma's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12M155-4%N/AN/A
#2
$17.3M22318%N/AN/A
#3
$11.1M14334%N/AN/A
#4
$8.2M1068%N/AN/A
#5
$9.5M12310%N/AN/A
#6
$21.2M2738%N/AN/A
#7
$12M1558%N/AN/A
#8
$18.9M2445%N/AN/A
#9
$12.5M1619%N/AN/A
#10
$20.5M2648%N/AN/A
Add Company

What Is Stelis Biopharma?

Stelis Biopharma Pvt. Ltd. (Stelis) is a fully vertically integrated biopharmaceutical company. Operations include R&D, process development and scale-up and end-to-end cGMP manufacturing capabilities from microbial Drug Substance manufacture through Drug Product manufacture in all formats and packaging. Stelis? state-of-the-art research & development facility and 200,000 sq. ft. fully integrated cGMP manufacturing facility are located in Bangalore, India. Facilities cater to the development and cGMP manufacture of biologics and injectables conforming to international standards including US FDA and European EMA. The principal shareholders of Stelis Biopharma are 1. Strides Pharma, Bangalore, India (www.strides.com) 2. Tenshi Life Sciences Pvt. Ltd, Bangalore, India (www.tenshi.co.in) 3. GMS Holdings, Amman, Jordan (www.gmsholdings.com)

keywords:N/A

N/A

Total Funding

547

Number of Employees

$42.4M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Stelis Biopharma News

2022-03-22 - Stelis Licenses Akston's AKS-452 Thermostable Protein ...

Akston Biosciences Corp., a developer of new classes of biologics, and Biolexis, a division of Stelis Biopharma Ltd., have entered into a...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$77.6M5477%N/A
#2
$94.3M55012%$44.6M
#3
$49.9M55113%N/A
#4
N/A5522%N/A
#5
$45.6M55218%$152M